A.I. BURNASYAN FMBC CLINICAL BULLETIN

ISSN 2782-6430 (print)

State Research Center −Burnasyan Federal Medical Biophysical
Center of Federal Medical Biological Agency

The journal is published in Russian.
Format – A4.
The periodicity of the journal is 4 times a year.

Issue №2, 2026

more

A.I. Burnasyan  FMBC clinical bulletin. 2026 № 2

L.S. Butaev 1,2, V.A. Zherebtsova1, M.S. Butaeva3, M.A. Sannikova1, M.V. Chernikov1, E.S. Urnova1,
D.G. Kisilchina1, M.P. Bulussov1, Yu.A. Kruchinkina1, V.V. Ptushkin1, T.A. Astrelina2

Is Venetoclax Effective in Combination with Standard Therapy for Relapses
of Diffuse Large B-Cell Lymphoma?

1S.P. Botkin Moscow Multidisciplinary Scientific and Clinical Center

2International Office, State Research Center – Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency, Moscow, Russiа

3MEDSI Clinical Hospital №1

Contact person: Astrelina Tatiana Alekseevna: t_astrelina@mail.ru

 

Abstract
Introduction: despite the success in the treatment of r/r DVCCL, the prognosis remains unfavorable. CSR in platinum-containing modes is less than 50%, PO is 30%. Phase I-II studies have shown that venetoclax increases sensitivity to chemotherapy. We present our data on the use of venetoclax with chemotherapy for r/r DVCCL.
Aim: to evaluate the efficacy and tolerability of chemotherapy in combination with venetoclax in comparison with standard approaches.
Materials and methods: a retrospective study included 128 patients with DVCCL after line 1 who were suitable for HSCT. Groups: Ven+ (n=23, R-DHAPven, R-GDPven, R-ICEven); Ven − (n=105, without venetoclax).
Results: the overall median was not reached (ND) (95% CI: 26 months – ND). Two-year OS 59% (95% CI: 49 – 67%). Median BSV was 8.5 months (95% CI: 4.0 – 24.0 months). Two-year BSV was 41% (95% CI: 32 – 49%).
In the Ven+ group, the two – year OS was 68% (95% CI: 44-83%), the median OS was not reached (95% CI: 15 months). In the Ven group (n = 105), the two−year OB was 57% (95% CI: 46-66%), and the median OB was not reached (95% CI: 21 months). The differences were not significant (p = 0.3).
In the Ven+ group, the two–year BSV was 51% (95% CI: 29-69%), the median BSV was not reached (95% CI: 3.5 months). In the Ven group, two−year BSV was 38% (95% CI: 29 – 48%), the median BSV was 5.4 months (95% CI: 3.6–18.0 months), the differences were not significant (p = 0.3). In the Ven+ group (n = 14), the two–year DO was 50% (95% CI: 23 – 72%), the median DO was 35 months (95% CI: 5.5 months – not reached). In the Ven group (n = 44), the two − year DO was 43% (95% CI: 28 – 57%), the median DO was 33 months (95% CI: 23 months – ND), the differences were not significant (p = 0.9).

Conclusions: venetoclax in the 2nd stage of r/r DVCL therapy increases the frequency of complete responses and overall responses, with a tendency to improve OS and BV, however, with a limited sample size, no statistically significant advantage has been achieved.

Keywords: venetoclax, relapsed or refractory Diffuse B-large cell lymphoma, achievement of a long-term response

For citation: Butaev LS, Zherebtsova VA, Butaeva MS, Sannikova MA, Chernikov MV, Urnova ES, Kisilchina DG, Bulussov MP, Kruchinkina YuA, Ptushkin VV, Astrelina TA. Is Venetoclax Effective in Combination with Standard Therapy for Relapses of Diffuse Large B-Cell Lymphoma?. A.I. Burnasyan Federal Medical Biophysical Center Clinical Bulletin. 2026.2:99-107. (In Russian) DOI: 10.33266/2782-6430-2026-2-99-107

 

REFERENCES

  1. Coiffier B., Thieblemont C., van de Neste E., et al. Long-Term Outcome of Patients in the LNH-98.5 Trial, the First Randomized Study Comparing Rituximab-CHOP to Standard CHOP Chemotherapy in DLBCL Patients: a Study by the Groupe D’etudes des Lymphomes de l’Adult. Blood. 2010;116;12:2040-5.
  2. Gisselbrecht C., Glass B., Mounier N., et al. Salvage Regimens with Autologous Transplantation for Relapsed Large B-cell Lymphoma in the Rituximab Era. J Clin Oncol. 2010;28;27:4184-90.
  3. Crump M., Kuruvilla J., Couban S., et al. Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014;32;34:3490-6.
  4. Imhoff G.W., McMillan A., Matasar M.J., et al. Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma: the Orcharrd Study. J Clin Oncol. 2017;35;5:544-51.
  5. Philip T., Guglielmi C., Hagenbeek A., et al. Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive non-Hodgkin’s Lymphoma. N Engl J Med. 1995;333;23:1540-5.
  6. Crump M., Neelapu S.S., Farooq U., et al. Outcomes in Refractory Diffuse Large B-cell Lymphoma: Results from the International SCHOLAR-1 Study. Blood. 2017;130;16:1800-8.
  7. Bastos-Oreiro M., Abrisqueta P., Gutierrez A., et al. New Therapies for Relapsed or Refractory Aggressive B-Cell Lymphoma Increase Survival: Analysis from the RELINF Registry of the Geltamo Group. Hemasphere. 2024;8;4:e70.
  8. Sun L.L., Ellerman D., Mathieu M., et al. Anti-CD20/CD3 T Cell-Dependent Bispecific Antibody for the Treatment of B-Cell Malignancies. Sci Transl Med. 2015;7;287:287ra70.
  9. Falchi L., Vardhana S.A., Salles G.A. Bispecific Antibodies for the Treatment of B-cell Lymphoma: Promises, Unknowns, and Opportunities. Blood. 2023;141;5:467-80.
  10. Stilgenbauer S., Eichhorst B., Schetelig J., et al. Venetoclax in Relapsed or Refractory Chronic Lymphocytic Leukaemia with 17p Deletion: a Multicentre, Open-Label, Phase 2 Study. Lancet Oncol. 2016;17;6:768-78.
  11. Nishida Y., et al. Enhanced TP53 Reactivation Disrupts MYC Transcriptional Program and Overcomes Venetoclax Resistance in Acute Myeloid Leukemias. Sci Adv. 2023;9;17:eadh1436.
  12. Shoukier M., et al. Activity of Venetoclax-Based Therapy in TP53-Mutated Acute Myeloid Leukemia. J Clin Oncol. 2019;37;15_suppl:7034.
  13. Avet-Loiseau H., Li J.Y., Facon T., et al. High Incidence of Translocations T(11;14)(q13;q32) and t(4;14)(p16;q32) in Patients with Plasma cell Malignancies. Cancer Res. 1998;58;24:5640-5.
  14. Stilgenbauer S., Eichhorst B., Schetelig J., et al. Venetoclax for Patients with Chronic Lymphocytic Leukemia with 17p Deletion: Results from the Full Population of a Phase II Pivotal Trial. J Clin Oncol. 2018;36;19:1973-80.
  15. Caimi P.F., Cashen A., Gallogly M., et al. Venetoclax Combined with R-ICE (VICER) for Second Line Treatment of Diffuse Large B-cell Lymphoma Refractory or Relapsed after Initial Chemoimmunotherapy. Hematol Oncol. 2023;41;Suppl 2:436-7.
  16. Morschhauser F., Feugier P., Flinn I., et al. A Phase II Study of Venetoclax Plus R-CHOP as First-Line Treatment for Patients with Diffuse Large B-cell Lymphoma. Blood. 2020;136;18:2081-9.
  17. Davids M.S., Roberts A.W., Seymour J.F., et al. Phase I First-in-Human Study of Venetoclax in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma. J Clin Oncol. 2017;35;8:826-33.
  18. Melani C., Lakhotia R., Pittaluga S., et al. Phase Ib/II Study of Multi-Targeted Therapy with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL). Blood. 2023;142;Suppl 1:261.
  19. Harrysson S., Eloranta S., Ekberg S., et al. Incidence of Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Including CNS Relapse in a Population-Based Cohort of 4243 Patients in Sweden. Blood Cancer J. 2021;11;10:168.
  20. Dogliotti I., Peri V., Clerico M., et al. Real Life Clinical Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma in the Rituximab Era: the Strider study. Cancer Med. 2024;13;3:e6845.
  21. Ip A., Mutebi A., Wang T., et al. Treatment Outcomes with Standard of Care in Relapsed/Refractory Diffuse Large B-cell Lymphoma: Real-World Data Analysis. Adv Ther. 2024;41;2:689-706.
  22. Tavakkoli M., Barta S.K. 2024 Update: Advances in the risk Stratification and Management of Large B-cell Lymphoma. Am J Hematol. 2024;99;1:92-109.
  23. Ohmoto A., Fuji S. Infection Profiles of Different Chemotherapy Regimens and the Clinical Feasibility of Antimicrobial Prophylaxis in Patients with DLBCL. Blood Rev. 2020;44:100738.
  24. Gisselbrecht C., Schmitz N., Mounier N., et al. R-ICE Versus R-DHAP in Relapsed Patients with CD20 Diffuse Large B-cell Lymphoma (DLBCL) Followed by Stem Cell Transplantation and Maintenance Treatment with Rituximab or Not: First Interim Analysis on 200 Patients. Coral study. Blood. 2007;110;11:517.
  25. Melani C., Lakhotia R., Pittaluga S., et al. Combination Targeted Therapy in Relapsed Diffuse Large B-cell Lymphoma. N Engl J Med. 2024;390;3:201-11.
  26. Jaeger U., Simonitsch-Klupp I., Klammer P., et al. Phase II Single-Arm Study of a Combination of Obinutuzumab and Venetoclax in Early Relapsed or Refractory Diffuse Large B-cell Lymphoma – Final Results of the AGMT NHL15B Study. Front Hematol. 2024;3:1331008.
  27. Yang M., Huang Y., Zhu L., et al. Clinical Study of Ibrutinib Combined with Venetoclax Regimen in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024;32;5:1323-9.

Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 13.03.2026. Accepted for publication: 15.04.2026

© 2026 Scientific journal - "Clinical Bulletin of the FMBС im. A.I. Burnasyan"
Scroll to Top